Authors:
McLeod, D
Zinner, N
Tomera, K
Gleason, D
Fotheringham, N
Campion, M
Garnick, MB
Citation: D. Mcleod et al., A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer, UROLOGY, 58(5), 2001, pp. 756-761
Authors:
Tomera, K
Gleason, D
Gittelman, M
Moseley, W
Zinner, N
Murdoch, M
Menon, M
Campion, M
Garnick, MB
Citation: K. Tomera et al., The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer, J UROL, 165(5), 2001, pp. 1585-1589
Authors:
Le Clainche, L
Rondelez, Y
Seneque, O
Blanchard, S
Campion, M
Giorgi, M
Duprat, AF
Le Mest, Y
Reinaud, O
Citation: L. Le Clainche et al., Calix[6]arene-based models for mono-copper enzymes: a promising supramolecular system for oxidation catalysis, CR AC S IIC, 3(10), 2000, pp. 811-819
Citation: Mb. Garnick et M. Campion, Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone, MOL UROL, 4(3), 2000, pp. 275-277
Authors:
Goodkin, DE
Priore, RL
Wende, KE
Campion, M
Bourdette, DN
Herndon, RM
Fischer, JS
Jacobs, LD
Cookfair, DL
Rudick, RA
Richert, JR
Salazar, AM
Granger, CV
Simon, JH
Alam, JJ
Bartoszak, DM
Braiman, J
Brownscheidle, CM
Coats, ME
Cohan, SL
Dougherty, DS
Kinkel, RP
Mass, MK
Munschauer, FE
Pullicino, PM
Scherokman, BJ
Weinstock-Guttman, B
Whitham, RH
Citation: De. Goodkin et al., Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials, MULT SCLER, 4(6), 1998, pp. 480-486